GlassScriptPhysician profile
Kunal P Patel
NPI 1720428329
$12,886.90
in general payments reported to CMS, 2019-2025
45 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,355 · 2020: $1,207 · 2021: $883 · 2022: $5,300 · 2023: $1,625 · 2024: $1,225 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,107 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.43 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,810.10 | 2022-2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,376.97 | 2019-2024 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,172.17 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $996.11 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $625.63 | 2019-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $509.41 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $402.34 | 2019-2024 | Orenitram, Tyvaso, Remodulin |
| Abbott Laboratories | $386.66 | 2022-2025 | Proclaim |
| Genzyme Corporation | $369.98 | 2019-2024 | |
| Grifols USA, LLC | $328.00 | 2019-2023 | Prolastin-C Liquid |
| Insmed, INC. | $275.44 | 2019-2024 | Arikayce |
| Amgen INC. | $243.58 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $224.47 | 2021-2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $206.36 | 2019-2023 | Dupixent |
| Philips North America LLC | $179.26 | 2019-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.